Results 61 to 70 of about 2,727 (172)

Resveratrol ameliorates prenatal progestin exposure-induced autism-like behavior through ERβ activation

Molecular Autism, 2018
Background Recent literatures indicate that maternal hormone exposure is a risk factor for autism spectrum disorder (ASD). We hypothesize that prenatal progestin exposure may counteract the neuroprotective effect of estrogen and contribute to ASD ...
Weiguo Xie, Xiaohu Ge, Ling Li, Athena Yao, Xiaoyan Wang, Min Li, Xiang Gong, Zhigang Chu, Zhe Lu, Xiaodong Huang, Yun Jiao, Yifei Wang, Meifang Xiao, Haijia Chen, Wei Xiang, Paul Yao   +15 more
doaj   +1 more source

The effect of Norethisterone acetate on the uterus of albino rats: histological, histochemical and ultrastructure study

BMC Veterinary Research
Background Norethisterone acetate (NETA), also known as norethindrone acetate is a progestogens medication that is widely used in birth control pills, menopausal hormone therapy, and for the treatment of gynecological disorders as abnormal uterine ...
Mahmoud Abd-Elkareem, Sulaiman Mohammed Alnasser, Alotaibi Meshal, Raghda Ismail Abdullah, Ahmed U. Ali   +4 more
doaj   +1 more source

Gestational Gigantomastia: A Century of Evidence with a New Case

Plastic and Reconstructive Surgery, Global Open
Background:. Gestational gigantomastia (GG) is an extreme, rapidly progressive breast enlargement that can culminate in ulceration, sepsis, cardiopulmonary compromise, and, when care is delayed, maternal death.
Sama K. Fofung, MD, MMed, Janan H. Malik, MBChB, MPH, MMed, Waluma M. Fofung, MA, Benjamin Wabwire, MBChB, MMed   +3 more
doaj   +1 more source

Comparing the risk of deep vein thrombosis of two combined oral contraceptives: Norethindrone/ethinyl estradiol and drospirenone/ethinyl estradiol

Heliyon
Background: Deep vein thrombosis (DVT) has been reported as an adverse event for patients receiving combined oral contraceptives. Norethindrone/ethinyl estradiol (NET/EE) and drospirenone/ethinyl estradiol (DRSP/EE) are two commonly prescribed combined ...
Jennifer Stalas, Robert Morris, Kun Bu, Kevin von Bargen, Rebekah Largmann, Kathryn Sanford, Jacob Vandeventer, Weiru Han, Feng Cheng   +8 more
doaj   +1 more source

A Novel Intrauterine Device for the Spatio-Temporal Release of Norethindrone Acetate as a Counter-Estrogenic Intervention in the Genitourinary Syndrome of Menopause

Pharmaceutics
The genitourinary syndrome of menopause (GSM) is a widely occurring condition affecting millions of women worldwide. The current treatment of GSM involves the use of orally or vaginally administered estrogens, often with the risk of endometrial ...
Ahmed Abdelgader, Mershen Govender, Pradeep Kumar, Yahya E. Choonara   +3 more
doaj   +1 more source

Comparison of Dermatologic and Neuropsychological Side Effects of Oral Contraceptives, 2016–2020

Open Access Journal of Contraception
Joseph Visingardi,1,* Paul J Feustel,2,* Rachel Flink-Bochacki,3,* Cassandra Denefrio3,* 1Internal Medicine, Albany Medical Center, Albany, NY, USA; 2Neuroscience and Experimental Therapeutics, Albany Medical College ...
Visingardi J, Feustel PJ, Flink-Bochacki R, Denefrio C   +3 more
doaj  

Genomic and transcriptomic characterization of a novel wastewater-derived Sporosarcina sp. with broad-spectrum bioremediation potential against endocrine disruptors and pharmaceuticals

Chemical Engineering Journal Advances
Emerging pollutants (EPs) such as pharmaceuticals, hormones, and pesticides are increasingly detected in aquatic environments due to their widespread use and incomplete removal by conventional wastewater treatment plants.
Sumayya Al Ali, Khadije Ahmad Amin, Aryam Alkaabi, Hima Vadakkeveettil Manoharan, Michael Olbrich, Ahmed F. Yousef, Habiba Al Safar, Syed Salman Ashraf, Gihan Daw Elbait   +8 more
doaj   +1 more source

Presurgical treatment of uterine myomas with the GnRH-antagonist relugolix in combination therapy: an observational study

Scientific Reports
To evaluate if a preoperative medical treatment with the GnRH-antagonist relugolix in combination therapy in a series of patients with abnormal uterine bleeding associated with uterine myomas may correct the anemia before scheduled surgery for myoma ...
Ludovico Muzii, Giulia Galati, Antonella Mercurio, Carlotta Olivieri, Letizia Scarcella, Ilham Azenkoud, Rossana Tripodi, Michele Vignali, Stefano Angioni, Antonio Maiorana   +9 more
doaj   +1 more source

Impact of demographic and clinical factors on elagolix plus add-back therapy effects on patient-reported nonbleeding symptoms in women with heavy menstrual bleeding and uterine fibroids: a post hoc analysis of data from two clinical trials

F&S Reports
Objective: To investigate the efficacy of elagolix plus add-back therapy (estradiol [1 mg] and norethindrone acetate [0.5 mg] once daily) on patient-reported nonbleeding symptoms and menstrual bleeding associated with uterine fibroids (UFs) across ...
James A. Simon, M.D., Elizabeth A. Stewart, M.D., Susan Jewell, Ph.D., Moming Li, Ph.D., Michael C. Snabes, M.D., Ph.D.   +4 more
doaj   +1 more source

Norethindrone [PDF]

, 2020
openaire   +1 more source